Geode Capital Management’s Lucid Diagnostics LUCD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.58M Buy
2,245,350
+218,523
+11% +$278K ﹤0.01% 3028
2025
Q4
$2.21M Buy
2,026,827
+352,654
+21% +$394K ﹤0.01% 3133
2025
Q3
$1.69M Buy
1,674,173
+96,804
+6% +$106K ﹤0.01% 3236
2025
Q2
$1.81M Buy
1,577,369
+1,274,194
+420% +$1.65M ﹤0.01% 3173
2025
Q1
$452K Buy
303,175
+23,671
+8% +$28.4K ﹤0.01% 3578
2024
Q4
$229K Buy
279,504
+65,964
+31% +$58.2K ﹤0.01% 3865
2024
Q3
$174K Buy
213,540
+9,185
+4% +$7.52K ﹤0.01% 3947
2024
Q2
$168K Buy
204,355
+48,598
+31% +$41.2K ﹤0.01% 3978
2024
Q1
$126K Buy
155,757
+23,886
+18% +$31K ﹤0.01% 4087
2023
Q4
$186K Hold
131,871
﹤0.01% 3969
2023
Q3
$154K Sell
131,871
-11,594
-8% -$16.8K ﹤0.01% 4085
2023
Q2
$199K Buy
143,465
+101,922
+245% +$154K ﹤0.01% 4040
2023
Q1
$58.2K Hold
41,543
﹤0.01% 4485
2022
Q4
$56K Buy
41,543
+2,427
+6% +$4.37K ﹤0.01% 4562
2022
Q3
$59K Buy
39,116
+3,640
+10% +$9.06K ﹤0.01% 4729
2022
Q2
$80K Sell
35,476
-49,801
-58% -$111K ﹤0.01% 4658
2022
Q1
$286K Buy
85,277
+39,973
+88% +$146K ﹤0.01% 4199
2021
Q4
$243K Buy
+45,304
New +$368K ﹤0.01% 4392

Other funds holding LUCD

Geode Capital Management's LUCD Position: Q1 2026 in Review

Geode Capital Management increased its Lucid Diagnostics (LUCD) stake by 11% in Q1 2026, buying an estimated $278K and bringing the position to 2,245,350 shares worth $2.58M. The position accounts for ﹤0.01% of the portfolio, ranked #3028.

Geode Capital Management first reported a position in LUCD in Q4 2021 and has held it in 18 quarters since. 103 funds tracked by Wall St. Rank hold LUCD as of Q1 2026.

  • Geode Capital Management held 2,245,350 shares of Lucid Diagnostics worth $2.58M as of Q1 2026.
  • Geode Capital Management bought 218,523 Lucid Diagnostics shares in Q1 2026, an estimated $278K.
  • Lucid Diagnostics made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #3028 holding.
  • Geode Capital Management first reported a position in Lucid Diagnostics in Q4 2021 and has held it in 18 quarters since.
  • 103 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.